Bedrijfsoverzicht
Citius Oncology, Inc. is primarily engaged in the development and commercialization of innovative targeted oncology therapies, with a specific focus on advancing LYMPHIR as an orphan indication for adult patients suffering from relapsed or refractory cutaneous T-cell lymphoma. The company operates within the Healthcare sector and specifically falls under the industry classification of Drug Manufacturers - Specialty & Generic, a segment characterized by high research and development costs and regulatory complexity. Currently, the entity maintains a market capitalization of $59.59M and generates annual revenue of $3.94M, while the precise count of employees is not disclosed in available filings. These valuation and revenue figures indicate that the company operates with a relatively small market footprint typical of early-stage biotechnology firms that are still navigating the path to commercial viability and widespread product adoption.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $3.94M, yet posted a significant net income loss of $-23,636,232, with no reported EBITDA, a disparity that reveals a cost structure where operating expenses vastly exceed revenue generation. This negative financial position is further evidenced by a free cash flow of $-24,720,178, which indicates that the company is consuming its cash reserves to fund operations and development efforts rather than generating surplus liquidity. The gross margin stands at 80.0%, suggesting that the cost of goods sold is managed efficiently relative to sales, yet the operating margin is severely negative at -133.2%, signaling that overhead and research costs are not covered by revenue. Additionally, the profit margin is recorded at 0.0%, reflecting the total lack of profitability at the bottom line. Regarding balance sheet leverage, the company holds $7.30M in cash against $3.80M in debt, resulting in a debt-to-equity ratio of 6.51, which suggests a highly leveraged capital structure relative to its equity base. Short-term liquidity appears constrained with a current ratio of 0.83, indicating that current assets are insufficient to cover current liabilities without additional financing or asset liquidation. Return on Equity is calculated at -47.4% and Return on Assets is -14.0%, metrics that collectively reveal management's current inability to generate positive returns on the capital invested by shareholders or utilized in assets.
Waarderingsbeoordeling
Trailing P/E and forward P/E ratios are both unavailable (N/A) due to the lack of net income, meaning standard earnings-based valuation multiples cannot be calculated to imply an earnings trajectory. However, the price-to-book ratio is 0.98, which indicates that the market values the company slightly below its book value, a common characteristic for loss-making biotechnology firms where future growth potential is priced rather than historical earnings. Alternative valuation metrics such as the price-to-sales ratio of 15.11 and an unavailable EV/EBITDA suggest that investors are pricing the stock based on revenue potential rather than profitability. The stock has traded between a 52-week low of $0.49 and a 52-week high of $6.19, providing a wide trading range that reflects significant price discovery and volatility. Although the current price is not explicitly stated in the source data, the wide spread between the high and low demonstrates the speculative nature of the equity. The beta value is 3.43, indicating that the stock's price volatility is more than three times that of the broader market, meaning price swings are amplified relative to standard market movements.
Growth & Income
The available data does not provide specific revenue growth or earnings growth rates (YoY), as these metrics are listed as N/A, preventing a direct comparison of earnings growth speed against revenue. Consequently, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Since there is no dividend income, the company does not distribute cash to shareholders but instead retains its limited cash resources to fund its ongoing development activities and research programs. This reinvestment strategy is typical for specialty drug manufacturers in the early commercialization phase who prioritize product advancement over income generation for existing shareholders. The overall growth and income profile is currently defined by high revenue volatility, significant cash burn, and a complete reliance on external capital or future product success rather than organic earnings growth or dividend yields.